FDA Expands Pediatric Approvals for Novo Nordisk’s Once-Weekly Growth Hormone Sogroya
Novo Nordisk said the US Food and Drug Administration has approved three additional pediatric indications for once-weekly Sogroya (somapacitan-beco) injections in fixed strengths of 5 mg, 10 mg, or 15 mg. The label now covers children 2.5 years and older with Idiopathic Short Stature (ISS), children born Small for Gestational Age (SGA) with persist…